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these 15 (60%) had achieved counts of> 20/ul on Day -1 itself
[median count of 45.3/ul (range: 21.4e130.2)]. None of the
patients had toxicity related to meloxicam. Subsequently 21
patients underwent auto SCT and their data was compared
with 50 age and disease matched controls who had
mobilization and auto SCT at our center between January
2013 and March 2014. Though mobilization rates and cell
doses were not signiﬁcantly different, the use of meloxicam
and G-CSF was associated with faster neutrophil engraft-
ment. Following auto SCT, there was lower Grade IIIeIV
toxicity, lower transfusion requirement of red cells and
reduction in the duration of hospital stay post SCT [Table 1].
Conclusion: The addition of meloxicam to G-CSF improves
stem cell mobilization and is associated with faster engraft-
ment, no additional toxicity, lower supportive care and lower
duration of hospitalization. It is also potentially possible that
we may be able to harvest the patients a day earlier
depending upon the peripheral blood CD 34 counts achieved.
This datawarrants a prospective randomized trial comparing
Meloxicam + G-CSF with G-CSF alone as a mobilization
strategy prior to autologous stem cell transplantation.Table 1
Vascath (15) CVL (12) p-value
Diagnosis
Neuroblastoma/
Ganglioneuroblastoma
8 7
CNS tumor 3 4
Retinoblastoma 1 0
Lymphoma 2 1
Ewing’s Sarcoma 1 0
Mean # pheresis days 1.2 (1-3) 1.3 (1-2) 0.62
Median weight (kg) 22 (10-120.9) 15.4 (7.45-45.6) 0.06
Median peripheral
blood absolute CD34
count day 1
206 (35.6-766) 354 (12.8-928) 0.5
Median CD34/kg
collected (X 106)
21.5 (6.5-111) 46.7 (13.3-101) 0.06
Median time from admit
to pheresis start
(minutes)
333 (190-607) 179 (80-453) 0.0002
Median total time on
machine (minutes)
245 (121-851) 281 (180-582) 0.3
Mean inlet ﬂow rate
(ml/min)
70.1 (15.9-128.5) 25.5 (9.8-54) 0.002
Mean inlet ﬂow rate/kg 1.56 (0.7-3.95) 2.22 (1.18-2.06) 0.03
Mean # pressure/ﬂow
error readings
0.6 (0-6) 2.4 (0-5) 0.01153
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Background: Early (<12 months from diagnosis) autologous
stem cell transplantation (ASCT) remains a standard treat-
ment for eligible patients with multiple myeloma (MM).
However studies suggest comparable overall survival (OS)
outcomes in patients undergoing delayed (>12 months from
diagnosis) ASCT. Little is known about the outcomes upon
relapse from a delayed ASCT and hence we describe the
natural course of the disease and identify factors that predict
post-ASCT relapse survival in this group of patients.
Patients and Methods: We examined the outcomes of 207
MM patients who underwent a delayed ASCT (12 or more
months from their initial diagnosis) at the Mayo Clinic,
Rochester and then relapsed between 2000 and 2012. Pa-
tients who received a tandem or an allogeneic stem cell
transplant post ﬁrst ASCT were not included in this study.
Multivariate analysis was performed using a Cox propor-
tional hazards model.
Results: Median (range) age at ASCT and at relapse was 62
yrs (40-75) and 63 yrs (40-76) respectively. The median time
to ASCT from MM diagnosis was 30 mos (12-202) and the
median time to relapse post-ASCT was 11 mos (2-100). The
median follow-up (95% CI) from relapse was 78 mos (60-99).
The median (range) number of regimens prior to ASCT was 2
(1-6). Of the 112 patients who had FISH testing at diagnosis,
30% were categorized as high risk. The median (95% CI) LDH
and plasma cell labeling index at diagnosis was 169
(178e215) and 0.6 (1e1.5) respectively. The median (95% CI)
post-ASCT relapse survival (PRS) and overall survival from
diagnosis was 30 (22-36) and 77 (69-87) mos, respectively.
The distribution (N, %) of the post-relapse treatment regi-
mens were as follows: immunomodulator-based (103, 50%),
proteasome inhibitor-based (47, 23%), non-novel agent
chemotherapy (31, 15%), novel investigational therapy (22,
11%) and repeat ASCT (4, 1%). In a multivariate analysis, only
shorter time to relapse, presence of CRAB symptoms orextramedullary disease at relapse, higher pre-ASCT plasma
cell labeling index and LDH predicted for a shorter PRS. The
presence of high-risk cytogenetics by FISH, and choice of
salvage therapy upon relapse post-ASCT did not affect PRS in
the multivariable model.
Conclusion: MM patients who undergo a delayed ﬁrst ASCT
experience improved PRS if they have a longer duration of
response to ASCT, lack CRAB symptoms or extramedullary
disease at relapse (only biochemical progression) and have a
lower pre-ASCT plasma cell labeling index and serum LDH.
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Background and Methods: Large bore venous catheters
such as Vas-cath or hemodialysis catheters are recom-
mended for stem cell pheresis but rarely placed for routine
chemotherapy requiring placement of a second line for
pheresis. Timing pheresis with count recovery and stem cell
collection can be logistically challenging. Due to these chal-
lenges and desire to avoid additional line placement and
anesthesia, we attempted to use double lumen central
venous lines (CVL) for stem cell pheresis in patients who had
them at the time of referral.
Results: Twenty-seven patients underwent stem cell phe-
resis for autologous stem cell transplant from January 2012
to October 2014 utilizing a Cobe Spectra. Patient character-
istics and results (as means/medians and ranges) are detailed
in Table 1. Double lumen CVL was used preferentially for
stem cell pheresis if there was one placed at diagnosis for
chemotherapy and present at time of referral. Thirteen
patients referred for stem cell pheresis had double lumen
CVL (usually 7-9 Fr double lumen Broviacs). The remaining
fourteen patients had either no central line or had
Table 2
Grade 3/4 Non-hematologic Toxicities
Preferred Term All Grades % (N¼61) Grade 3/4 % (N¼61)
Diarrhea 93 3
Nausea 90 2
Fatigue 77 2
Hypokalemia 74 28
Vomiting 64 0
Hypophosphatemia 49 48
Decreased Appetite 49 0
Pyrexia 48 3
Constipation 48 0
Febrile Neutropenia 41 28
Mucosal Inﬂammation 38 10
Dizziness 38 0
Stomatitis 28 5
Abdominal Pain 28 0
Dysgeusia 28 0
Dyspepsia 26 0
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morning of pheresis. Twelve patients completed pheresis
and reached target CD34 collection through double lumen
CVL. One patient was unable to complete pheresis via his
CVL and had a successful pheresis the following day after
Vascath placement. Median inlet ﬂow rates were
signiﬁcantly lower in patients undergoing pheresis with a
double lumen CVL when compared to patients undergoing
pheresis via Vascath and there was a signiﬁcantly higher
rate of pressure error readings in patients with CVLs. Time
from admission to start of pheresis was signiﬁcantly less in
patients who underwent pheresis with a CVL. There was no
signiﬁcant difference in time on machine, CD34/kg
collected, or number of days of pheresis.
Conclusion: Hematopoietic stem cell pheresis utilizing dou-
ble lumenCVL is feasiblewith the potential beneﬁts of shorter
hospitalization and avoidance of second line placement.155
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Melphalan 200 mg/m2 IV is the most common conditioning
regimen for AHCT in MM. Conventional melphalan formu-
lations (eg, Alkeran) have marginal solubility, limited
chemical stability and require PG as a co-solvent, which is
associated with renal dysfunction and arrhythmias. Captisol-
enabled Melphalan HCL (CE-Melphalan) is a PG-free formu-
lation of melphalan that incorporates Captisol, a modiﬁedTable 1
Patient Characteristics
Total (N[61)
Median Age (range) in yrs 62 (32-73)
Age ‡ 65 yrs 30%
Male Gender 57%
Race
White 80%
Black/African American 18%
Other 2%
ECOG Status
0 59%
1 38%
2 3%
Disease Status Pre-treatment
sCR 0%
CR 5%
VGPR 44%
PR 32%
Disease Status at Day 100 post-AHCT
sCR 13%
CR 8%
VGPR 61%
PR 18%cyclodextrin that improves its solubility, stability and
bioavailability. In a previous Phase 2 study, CE-Melphalan
was shown to be bioequivalent to Alkeran.
Methods: This Phase II, open-label study enrolled 61 pts with
MMwho received 200 mg/m2 of CE-Melphalan (100 mg/m2/
day x 2) followed by AHCT. Most subjects were male (57%)
with a median age of 62.0 years (range 32-73), including 56
(92%) subjects who received upfront AHCT and 5 (8%) after
relapse (Table 1). Median lines of prior therapy was 3 (range
2-16). High risk cytogenetics in 6 (10%) pts. Disease status at
pre-treatment included CR in 3 subjects, VGPR in 27 and PR
in 20 subjects.
Results: All subjects achieved myeloablation followed by
successful engraftment. Median time to neutrophil engraft-
ment was 12 days post-AHCT (range: 10-12); time to platelet
engraftment was 13 days (range 10-28). There was no mor-
tality by Day 100, and as expected the most common Grade 3
and 4 toxicities were hematologic. Non-hematologic toxic-
ities are summarized in Table 2. Severe mucositis was
reported in few patients (Grade 3/4; 10%). At Day 100 post-
AHCT, all patients (100%) had a response with 82% of subjects
achieving a>¼ VGPR response including sCR in 13%, CR in 8%
and VGPR in 61%.
Conclusions: CE-Melphalan led to successful myeloablation
and subsequent engraftment inMMpatients with nomortality
or unexpected transplant-related toxicity over conventional
melphalan. The incidence of Grade 3-4 mucositis was low.
Overall,100% of subjects responded to high doseCE-Melphalan,
and in the subgroup of high risk patients (n¼6, 10%), an
encouraging 67% VGPR or better responses were achieved.156
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In the post combination antiretroviral therapy (cART) era,
HIV infected patients are better able to tolerate chemo-
therapy for HIV-associated lymphoma and results of the
treatment are similar now to non-HIV infected patients.
Consequently the use of hematopoietic stem cell trans-
plant (HSCT) has been investigated in the post cART era.
One of the main challenges that faces clinicians though is
the potential for cART and chemotherapy drug-drug
interactions.
